Rezolute is trading 5.21% up at $4.54 after the FDA recommended that the company request a pre-BLA meeting for ersodetug. - The recommendation followed the FDA’s October 5 review of Phase 3 sunRIZE data; the trial missed its primary and key secondary endpoints. - The FDA did not determine whether ersodetug is approvable; that would be assessed in a formal BLA review. - Shares are up 5.21% during live trading while the biotech sector is down, supporting a company-specific catalyst.